CRL — Charles River Laboratories International, Inc. Common Stock

Why people talked about CRL (2026-11-05)

• Charles River Laboratories reported Q3 2026 net income of $333.1M, driven by a $201M tax-benefit reversal, despite a 2.2% YoY revenue decline.
• The company raised its 2026 guidance, although operating cash flow fell 19.5% and nine-month income was reduced by divestiture losses.
• Earnings quality is questioned as headline profits rely heavily on the tax reserve reversal rather than core operational growth.